Eurofins Scientific reports in-line 1H25 results with continued margin growth

Eurofins Scientific reported H1 2025 results largely in line with revenue expectations at €3,612 million, while adjusted EPS of €1.83 beat consensus by 5% and adjusted EBITDA margins improved to 22.4%. Organic growth was a modest 2.9%, with mixed regional performance as North America accelerated but Europe slowed, and the BioPharma segment remained weak. Despite maintaining full-year guidance for mid-single-digit organic growth and improved profitability, the company faces a significant challenge to generate over €600 million in free cash flow in H2, compared to €354 million in H1, to meet targets. Analysts at Jefferies maintain a €46.00 price target, implying 27% downside from Eurofins' current share price.

Analysis

Eurofins Scientific's first-half 2025 results present a mixed operational picture despite a headline beat on profitability. While revenues of €3,612 million were in line with consensus and adjusted EPS grew 18% to €1.83, exceeding estimates, the underlying organic growth of 2.9% remains modest. A key concern is the regional divergence, with accelerating growth in North America (4.1% in Q2) being offset by a significant slowdown in Europe (1.6% in Q2 from 2.9% in Q1). Furthermore, the critical BioPharma segment remains weak, posting only 1.5% growth. The balance sheet shows signs of pressure, with net debt to EBITDA rising to 2.1x, a figure flattered by a €200 million hybrid, and a notable increase in working capital outflow. Although the company maintained its full-year guidance, its credibility hinges on a substantial second-half performance, particularly in generating over €600 million in free cash flow to meet its target, a significant acceleration from the €354 million (excluding site investments) generated in H1. This challenging outlook is compounded by a Jefferies price target that implies 27% downside from the current stock price.

Key Decisions for Investors

• Investors should weigh the positive 18% year-over-year growth in adjusted EPS against fundamental challenges, including decelerating growth in Europe, persistent weakness in the BioPharma segment, and rising balance sheet leverage.
• It is critical to monitor the company's ability to meet its heavily back-end loaded free cash flow guidance, as the requirement to generate over €600 million in the second half poses a significant execution risk.
• Consider the substantial downside risk highlighted by Jefferies' price target of €46.00, which suggests the stock may be overvalued relative to its operational headwinds and execution challenges.
• Factor in potential future pressure on reported earnings from as-yet-unquantified Synlab restructuring costs, which are not included in the current financial reporting.